Xiwei Bio Announces Tens of Millions RMB Series A Financing Led by Daotong Investment to Build an Ophthalmic Biomaterials and Polymer Innovation Platform

VCBeat learned recently,EOSVISION (Suzhou) Biomedical Technology Co., Ltd. (hereinafter referred to as "EOSVISION") has completed a multi-million yuan Series A round of financing, led by Dalton Venture.. This round of financing will be used to accelerate the research and development, clinical trials, international development, registration, and marketing expansion of innovative ophthalmology and regenerative medicine products, including artificial biomimetic cornea, implantable contact lenses, artificial corneal endothelial patches, and artificial dermis.

EOSVISION was founded in 2020, focusing on the development of innovative products using novel bio-modified materials for ophthalmic implant medical devices and regenerative medicine devices. The core founding team members have over fifteen years of R&D and management experience in pharmaceutical-related fields both internationally and in China. The company has approximately 5,600 square meters of R&D and production space, with three static ISO 7 clean production workshops (locally static ISO 5) already built. It has established a comprehensive quality system in accordance with ISO13485, FDA QSR820, and China's Good Manufacturing Practice for Medical Devices.

In China, corneal disease is the third leading cause of blindness, with approximately 4 million people suffering from corneal blindness. Nearly half of these patients could regain their sight through corneal transplantation, and an additional 70,000 to 100,000 patients are added each year. However, no more than 10,000 corneal transplant surgeries are performed annually in China. Moreover, current solutions have various drawbacks such as aqueous humor leakage, glaucoma, and dissolution or detachment caused by rejection. Therefore,The Clinical Demand for Corneal Transplants and Corneal Endothelial Products is Far from Being Met, indicating a huge and rigid market prospect. At the same time, about 600 million people in China are nearsighted, and currently, there are approximately 2.2 million femtosecond refractive surgeries performed annually in China. Implantable contact lenses (ICL), with advantages such as no need to cut corneal tissue, simple surgical procedures and postoperative care, and the ability to be removed and replaced, are increasingly gaining favor among doctors and patients.

In response to the aforementioned clinical pain points and vast market, the company has developed a range of innovative medical devices. Its R&D pipeline includes artificial biomimetic cornea, implantable contact lenses, artificial corneal endothelium, artificial dermis, and more. Based on globally leading and proven industry patents, the company has developed key technologies for cross-linking copolymers of polymer materials and synthetic self-assembling triple-helix structured biomimetic gel raw materials, enabling its products to possessSignificant advantages such as improved biocompatibility, reduced protein adhesion, decreased calcification deposition, and controllable physicochemical properties.

Currently, the application of artificial bionic cornea in lamellar transplantation has entered the clinical trial stage. The technology effectively addresses the transparency and biocompatibility issues of the implanted products. Patients experience no rejection and minimal inflammatory response post-surgery, eliminating the need for lifelong use of anti-rejection and hormone medications. Another core product of the company, the implantable contact lens, is currently in the animal evaluation stage. Test results show that the optical technical parameters and animal safety of the company’s product can rival mainstream international products already on the market. Additionally, the use of synthetic collagen bionic peptides is expected to resolve the religious usage limitations associated with animal-derived collagen in existing marketed products, laying a foundation for the company’s products to enter the international market.

EOSVISION is committed to restoring vision for millions of blind people and improving the visual quality for tens of millions of people with myopia. It focuses on researching biomimetic fusion materials that cross the boundaries of biomass, polymers, and small molecules, and develops internationally leading medical devices to meet product demands in human optics, biological scaffolds (fillers), and regenerative repair.

Regarding this round of financing, the founder of EOSVISION stated: The success of this round of financing will strongly drive the progress of R&D for existing products. With the joint efforts of all employees and shareholders, we aim to bring our products to market as soon as possible, alleviating patients' suffering and enabling China's ophthalmic medical devices to rank among the world's best. All employees consistently uphold the belief that EOSVISION is a ray of dawn guarding human health, bringing light and hope to patients!

Dalton Venture stated：The company's technological patents are leading, and its products can be used in multiple implantation scenarios that require biocompatibility/optical performance. It has also built an experienced R&D, production, registration, and quality management team, showing the potential to grow into a platform-based enterprise. We are highly looking forward to working with EOSVISION to promote the launch of innovative products and bring clear vision benefits to numerous patients.

Dalton Venture focuses on forward-looking medical innovation technologies and is the early exclusive investor in several pioneering technology projects in China. It covers both VC funds and angel funds in the Yangtze River Delta and Greater Bay Area. The core team comes from the healthcare industry, having successfully incubated early-stage startups and established and managed listed companies with a market value of over tens of billions. Committed to not only being a value discoverer but also a value creator, Dalton Venture has been honored with multiple awards such as VC TOP100 and Medical Device TOP20 by ChinaVenture. Some investment cases include Landing Diagnostics, Hannovir Healthcare, Triastek, Hycan Biopharma, Bright Biotech, Shuimu Molecular, Stardust Intelligence, etc.